GleamWall
中文EN

SIGY Sigyn Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1642159 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.3%
TTM EPS YoY39.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,144.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets4,464.7%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-811.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31
Income statement
Revenue——
R&D expense$773,279$798,165
SG&A expense$1.74M$1.66M
Operating income-$2.52M-$2.46M
Pretax income-$3.34M-$4.15M
Net income-$3.34M-$4.15M
EBITDA-$2.51M-$2.45M
EPS (basic)-2.51-3.77
EPS (diluted)-2.51-3.77
Weighted avg. shares (diluted)1.33M1.10M
Balance sheet
Cash & equivalents$12,144$11,690
Inventory—$50,000
Current assets$21,244$118,063
PP&E, net$9,685$15,296
Total assets$213,719$321,806
Current liabilities$4.61M$3.61M
Short-term debt$0—
Long-term debt$2.02M$2.51M
Total debt$2.02M$2.51M
Total liabilities$4.67M$3.73M
Shareholders' equity-$4.46M-$3.41M
Net debt$2.01M$2.50M
Shares outstanding1.61M1.29M
Cash flow statement
Operating cash flow-$872,436-$1.38M
Financing cash flow$872,890$1.39M
Depreciation & amortization$5,611$6,756
Stock-based compensation$150,000$215,558

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.